{
    "clinical_study": {
        "@rank": "85867", 
        "arm_group": [
            {
                "arm_group_label": "Placebo Gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "6 mL of Placebo Gel administered TID for 6 weeks"
            }, 
            {
                "arm_group_label": "OLT1177 Gel", 
                "arm_group_type": "Experimental", 
                "description": "6 mL of OLT1177 Gel (5%) administered TID for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this trial are to investigate the efficacy and safety of six weeks of\n      treatment with OLT1177 Gel in subjects with moderate to severe pain associated with\n      osteoarthritis of the knee following cessation of pain therapy."
        }, 
        "brief_title": "Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain", 
        "condition": [
            "Osteoarthritis", 
            "Pain"
        ], 
        "condition_browse": {
            "mesh_term": "Osteoarthritis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 45 to 80 years old, inclusive\n\n          -  Clinical diagnosis of osteoarthritis in one target knee based on the following\n             American College of Rheumatology (ACR) criteria:\n\n               1. Knee Pain\n\n               2. At least 1 of 3:\n\n                    -  Age > 50 years\n\n                    -  Morning stiffness lasting < 30 minutes\n\n                    -  Crepitus on motion\n\n               3. Osteophytes on radiograph\n\n          -  Symptoms associated with osteoarthritis of the knee (including pain) for \u2265 6 months\n             prior to Screening\n\n          -  Knee pain associated with osteoarthritis, which required NSAID or other therapy for \u2265\n             15 days during the preceding month\n\n          -  Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a\n             rating of Grade 2 or 3 in the target knee (does not include borderline Grade 2), as\n             confirmed by the Sponsor's designated rheumatologist through radiographic review of\n             x-ray(s) taken no more than 1 year prior to the Screening visit. (Sharpening of the\n             tibial spine is not considered to be an osteophyte) (See Appendix 4 for additional\n             details)\n\n          -  Meets pain assessment entry criteria as defined by Sponsor's pain eligibility\n             algorithm and calculated by the study Interactive Web Response System\n\n          -  No clinically significant change in physical activity and/or therapy for the past 3\n             months\n\n          -  Able to provide written informed consent prior to initiation of any clinical\n             trial-related procedures; and willing and able, in the opinion of the Investigator,\n             to comply with all requirements of the clinical trial for the duration of the trial\n             (such requirements include, but are not limited to: attending all study visits,\n             refraining from elective surgery or extensive travel during participation)\n\n        Exclusion Criteria:\n\n        General\n\n          -  Women of childbearing potential, or men whose sexual partner(s) is a woman of\n             childbearing potential may not be entered into the study if:\n\n               1. They are or intend to become pregnant (including use of fertility drugs) during\n                  the study\n\n               2. They are nursing\n\n               3. They are not using an acceptable, highly effective method of contraception until\n                  all follow-up procedures are complete. (Acceptable, highly effective forms of\n                  contraception are defined as: oral contraception, intrauterine device, systemic\n                  [injectable or patch] contraception, double barrier methods, naturally or\n                  surgically sterile, strict abstinence or partner has been sterilized.  If\n                  hormonal-based birth control is being used, subject or subject's sexual\n                  partner(s) must be on a stable-dose for \u2265 3 months prior to the Baseline visit\n                  and maintained at the same dosing level throughout the 9-week clinical trial.)\n\n          -  Body Mass Index (BMI) over 40\n\n          -  A history of osteoarthritis symptoms that are completely non-responsive to\n             non-steroidal anti-inflammatory drugs (NSAIDs) at the discretion of the Investigator\n\n          -  Planned change (increase or decrease) in subject's level of physical activity (e.g.,\n             aerobic or anaerobic exercise) during the 6-week Treatment Period following\n             randomization\n\n          -  Enrollment in any trial and/or use of any Investigational Drug or device within the\n             immediate 30-day period prior to the Baseline visit\n\n          -  Enrollment in any study previously sponsored by Olatec Industries LLC, specifically\n             Study OLT1177-01 or OLT1177-02\n\n        Pain Related\n\n          -  Does not meet pain assessment entry criteria as defined by Sponsor's pain eligibility\n             algorithm and calculated by the study Interactive Web Response System\n\n          -  Clinically significant joint (other than the knee) or general pain at Baseline, at\n             the discretion of the Investigator\n\n        Musculoskeletal Related\n\n          -  Clinically significant, excessive effusion heat and/or redness in the target knee as\n             determined by the Investigator\n\n          -  Knock-kneed or bow-legged, as defined by a valgus or varus deformity of \u2265 15 degrees\n\n          -  Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a\n             rating of Grade 0, 1 or 4 in the target knee, as confirmed by the Sponsor's\n             designated rheumatologist through radiographic review of x-ray(s) taken no more than\n             1 year prior to the Screening visit (sharpening of the tibial spine is not considered\n             to be an osteophyte)\n\n          -  Documented history of clinically significant pain associated with osteoarthritis of\n             the spine or hips, at the discretion of the Investigator\n\n          -  Significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or\n             chondromalacia\n\n          -  Clinically significant medio-lateral and/or anterior-posterior instability, at the\n             discretion of the Investigator\n\n          -  Open surgery of the target knee within the prior year or surgery to the contralateral\n             knee or other weight-bearing joint within the prior year, if at the discretion of the\n             Investigator it would interfere with the study. If subject had open surgery more than\n             one-year prior, Sponsor's designated rheumatologist must confirm that such surgery\n             did not have any negative impact or consequence to the target knee (e.g., deformity\n             of angle to the bone, bone on bone, locking joints, etc.)\n\n          -  Arthroscopic surgery of the target knee within the prior six months\n\n          -  Any acute or chronic injury, other than osteoarthritis in the target knee, that will\n             be treated during the trial with any medication not allowed during the Treatment\n             Period\n\n          -  Prior surgery of the target knee requiring insertion of a medical device or surgical\n             hardware (e.g., screws)\n\n          -  Any major trauma or injury (including sports injuries) to the target knee in the past\n             12 months\n\n          -  Documented history of inflammatory joint disease, including but not limited to:\n             rheumatoid arthritis, gout, pseudogout, Paget's disease, psoriatic arthritis,\n             ankylosing spondylitis, chronic inflammatory disease (e.g., colitis), fibromyalgia\n             (diagnosed in accordance with ACR criteria, as applicable), articular fracture,\n             ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary\n             osteochondromatosis, heritable disorders (e.g., hypermobility) or collagen gene\n             mutations\n\n          -  Any planned interventional and/or surgical procedure during the 6-week Treatment\n             Period following randomization\n\n        Concomitant Conditions, Diseases, Medications/Therapies and Medical History Related\n\n          -  Any use of Rescue Medication within 24 hours prior to the Baseline visit or use of\n             any other pain medication within 7 days prior to Baseline visit\n\n          -  Uncontrolled hypertension, defined as blood pressure \u2265 150/95 mmHg\n\n          -  A history of uncontrolled and untreated diabetes mellitus with an HbA1c level > 8; or\n             blood sugar levels that are outside of the normal range and HbA1c level > 8 is\n             subsequently confirmed\n\n          -  Any inflammatory skin condition over the target knee application area\n\n          -  Use of any prohibited concomitant medications/therapies during the 7-day Washout\n             Period or planned use of any prohibited concomitant medications/therapies during the\n             6 week Treatment Period\n\n          -  Use of intraarticular or intramuscular steroids in the target knee within the\n             previous 3 months or in any other joint within the previous 30 days\n\n          -  Use of intraarticular hyaluronate in the target knee within the previous 6 months or\n             in any other joint within the previous 30 days\n\n          -  Current substance abuse or history of chronic substance abuse within the past year,\n             or prior chronic substance abuse (including alcoholism and/or addiction to pain\n             medications) that is determined at the discretion of the Investigator as likely to\n             interfere with trial assessments or recur during the trial\n\n          -  Use of any systemic (oral or parenteral) corticosteroids within the prior month\n\n          -  Uncontrolled psychiatric conditions (e.g., mania, depression, anxiety, substance\n             dependence of any kind) that would impair the subject from safely participating in\n             the trial, including completing any protocol requirements\n\n          -  Evidence of cognitive impairment including dementia that may interfere with subject's\n             ability to complete daily pain diaries requiring recall of average pain level in the\n             past 24 hours\n\n          -  Significant cardiovascular, respiratory, renal, hepatic, gastrointestinal,\n             hematological or neurological disease or prior surgery that may interfere with the\n             subject successfully completing the trial, including completing any protocol\n             requirements as determined by the Investigator\n\n          -  History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or\n             antibodies to Hepatitis C Virus (HCV)\n\n          -  Diagnosed with any form of cancer within the past 5 years, except for treated basal\n             cell or squamous cell carcinoma of the skin\n\n          -  Any other medical conditions, diseases or prior surgeries that in the opinion of the\n             Investigator would impair the subject from safely participating in the trial and/or\n             completing any protocol requirements\n\n          -  Active infection within 3 days of the Baseline visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104050", 
            "org_study_id": "OLT1177-03"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo Gel", 
                "description": "6 mL of Placebo Gel administered TID for 6 weeks", 
                "intervention_name": "Placebo Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "OLT1177 Gel", 
                "description": "6 mL of OLT1177 Gel (5%) administered TID for 6 weeks", 
                "intervention_name": "OLT1177 Gel", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "recruiting@accelclinical.com", 
                    "last_name": "Angela Hammerle", 
                    "phone": "205-757-8208"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35216"
                    }, 
                    "name": "Achieve Clinical Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Hayes Williams, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Brigitte Adamsen", 
                    "phone": "602-863-6363"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85023"
                    }, 
                    "name": "Arizona Research Center, Inc."
                }, 
                "investigator": {
                    "last_name": "Joseph Gimbel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Barbara Nu\u00f1ez", 
                    "phone": "520-219-6394"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85704"
                    }, 
                    "name": "Genova Clinical Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Leah Schmidt, DO, CPI", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Sharyn Plunkett", 
                    "phone": "805-969-2560"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Barbara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93108"
                    }, 
                    "name": "H. Richard Barthel, Inc."
                }, 
                "investigator": {
                    "last_name": "H. Richard Barthel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gail Hopkins", 
                    "phone": "203-386-3115"
                }, 
                "facility": {
                    "address": {
                        "city": "Milford", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06460"
                    }, 
                    "name": "Clinical Research Consulting, LLC"
                }, 
                "investigator": {
                    "last_name": "Susann Varano, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mphillips@availclinical.com", 
                    "last_name": "Megan Phillips", 
                    "phone": "386-785-2400"
                }, 
                "facility": {
                    "address": {
                        "city": "DeLand", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "Avail Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Bruce G. Rankin, DO, CPI", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Smith", 
                    "phone": "561-741-2033"
                }, 
                "facility": {
                    "address": {
                        "city": "Jupiter", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33458"
                    }, 
                    "name": "Health Awareness, Inc."
                }, 
                "investigator": {
                    "last_name": "Ronald Surowitz, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Liz Uchello", 
                    "phone": "504-897-5211"
                }, 
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70115"
                    }, 
                    "name": "Best Clinical Trial, LLC"
                }, 
                "investigator": {
                    "last_name": "George Walker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Marlene Mullaney", 
                    "phone": "443-444-4872"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21239"
                    }, 
                    "name": "Peter A. Holt, MD"
                }, 
                "investigator": {
                    "last_name": "Peter A Holt, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Joseph Velikis", 
                    "phone": "314-972-9600"
                }, 
                "facility": {
                    "address": {
                        "city": "Hazelwood", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63042"
                    }, 
                    "name": "Healthcare Research Network, Inc."
                }, 
                "investigator": {
                    "last_name": "Larry Reed, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patricia Feole", 
                    "phone": "401-739-9350"
                }, 
                "facility": {
                    "address": {
                        "city": "Warwick", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02886"
                    }, 
                    "name": "Omega Medical Research"
                }, 
                "investigator": {
                    "last_name": "David Fried, MD, FACP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Erica Degroff", 
                    "phone": "843-789-3703"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29406"
                    }, 
                    "name": "Clinical Trials of South Carolina"
                }, 
                "investigator": {
                    "last_name": "Edward Tavel, Jr., MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2b Randomized, Double-Blind, Vehicle-Controlled, Repeat-Dose, Multi- Center, Efficacy and Safety Clinical Trial of Topically Applied OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee Following Cessation of Pain Therapy", 
        "other_outcome": [
            {
                "description": "A standard physical examination covering the major body systems will be completed at the Screening, Baseline (prior to randomization) and Week 6 visits.", 
                "measure": "Physical Examination", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Week 8"
            }, 
            {
                "description": "Pulse, resting blood pressure, temperature and respiration will be collected.", 
                "measure": "Vital Signs", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Week 8"
            }, 
            {
                "description": "Blood will be drawn for hematology and chemistry laboratory analysis will be performed.", 
                "measure": "Safety Laboratory Measures", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Week 8"
            }, 
            {
                "description": "Adverse events will be collected starting immediately after the ICF is signed and continuing through Week 8.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Screening through Week 8"
            }
        ], 
        "overall_contact": {
            "email": "inquiries@olatecindustries.com", 
            "last_name": "Olatec Inquiries"
        }, 
        "overall_official": {
            "affiliation": "Cu-Tech, LLC", 
            "last_name": "William Cunningham, MD, FAAD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'", 
            "measure": "Pain on Movement", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104050"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'", 
                "measure": "Current Knee Pain", 
                "safety_issue": "No", 
                "time_frame": "Baseline (pre-dose) to Baseline (50-min post-dose)"
            }, 
            {
                "description": "The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.", 
                "measure": "WOMAC Pain Subscale", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 2, 4 and 6"
            }, 
            {
                "description": "The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.", 
                "measure": "WOMAC Physical Function Subscale", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 2, 4 and 6"
            }, 
            {
                "description": "Subjects will complete the assessment on a 100-mm Visual Analog Scale (with anchors 0=very good; 100=very poor) in response to the question, 'Considering all the ways osteoarthritis affects you, how well are you doing?'", 
                "measure": "Global Rating of Disease", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 2, 4 and 6"
            }, 
            {
                "description": "After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'", 
                "measure": "Current Knee Pain", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Hours 2-6"
            }, 
            {
                "description": "The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.", 
                "measure": "WOMAC Stiffness Subscale", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 2, 4 and 6"
            }, 
            {
                "description": "Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'", 
                "measure": "Pain on Movement (VAS, in-clinic)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 2, 4 and 6"
            }, 
            {
                "description": "All evaluations will be on the 11-point Numerical Rating Scale (with anchors 0=no pain; 100=extreme pain) and in response to the following instructions: Please put an \"X\" over the one number below that best describes your average study knee pain while moving during your daily activities since you woke up this morning.", 
                "measure": "Pain on Movement (11-point NRS, diary)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Week 6"
            }, 
            {
                "description": "Subjects will record the amount, time/date and dose of Rescue Medication use throughout the trial.", 
                "measure": "Use of Rescue Medication", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Week 6"
            }, 
            {
                "description": "The SF-12v2 Health Survey is a multipurpose short-form (SF) general health survey comprised of 12 questions to measure functional health and well-being from the subject's perspective.", 
                "measure": "Short Form 12v2 Health Survey", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 2, 4 and 6"
            }
        ], 
        "source": "Olatec Industries LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Olatec Industries LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}